An investigation into the effect of cimetidine pre-treatment on raft formation of an anti-reflux agent.
It is now becoming common practice to co-administer H2-receptor antagonists and anti-reflux agents in the treatment of reflux oesophagitis. The mechanism by which anti-reflux agents achieve flotation requires a small amount of gastric acid to be present in the stomach. This study investigated whether an anti-reflux agent would remain effective after the decrease in acid secretion produced by a typical clinical dosage regimen of cimetidine (400 mg q.d.s., 7 days). Gastric distribution and residence of a meal and an anti-reflux agent were assessed in 12 normal subjects using gamma scintigraphy. The area under the gastric and fundal emptying curves demonstrated that Liquid Gaviscon (sodium alginate compound) had a significantly greater gastric residence than the meal, both during the control period and after cimetidine pretreatment, and that the majority of the Gaviscon was located in the fundus. The distribution of Gaviscon into the fundus was not affected by cimetidine pretreatment. Cimetidine pre-treatment slightly, but not significantly, increased the time for half the meal and the Gaviscon to empty from the stomach. The results suggest that the mechanism of action of Liquid Gaviscon is not compromised by concurrent H2-antagonist therapy.
Washington
N
N
Department of Surgery, Queen's Medical Centre, Nottingham, UK.
Wilson
C G
CG
Williams
D L
DL
Robertson
C
C
D000464:Alginates / Q000493:pharmacokinetics*; D000536:Aluminum Hydroxide / Q000493:pharmacokinetics*; D002927:Cimetidine / Q000008:administration & dosage / Q000494:pharmacology*; D004338:Drug Combinations; D004435:Eating; D005260:Female; D005744:Gastric Acid / Q000378:metabolism; D005746:Gastric Emptying / Q000187:drug effects*; D005748:Gastric Fundus / Q000187:drug effects; D005753:Gastric Mucosa / Q000378:metabolism*; D006801:Humans; D008297:Male; D011877:Radionuclide Imaging; D012824:Silicic Acid / Q000493:pharmacokinetics*; D017693:Sodium Bicarbonate / Q000493:pharmacokinetics*; D013670:Sodium Pertechnetate Tc 99m; D013270:Stomach / Q000000981:diagnostic imaging
D000464:Alginates; D004338:Drug Combinations; D012824:Silicic Acid; D000536:Aluminum Hydroxide; C007829:alginate, aluminium hydroxide, magnesium trisilicate, sodium bicarbonate drug combination; D002927:Cimetidine; D017693:Sodium Bicarbonate; D013670:Sodium Pertechnetate Tc 99m